ACHC

AI Memo

Acadia Healthcare

As of 2026-10-02/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Derivative-settlement approval hearing • 2026-12-10

Base target: $30 / p=45% prob

Biggest risk

Q2 adjusted EBITDA fell to $149.2 million from $201.8 million a year earlier. Flat same-facility revenue, Pennsylvania specialty-facility weakness, a $28.6 million liability-reserve adjustment and 4.1x net leverage leave the recovery exposed to execution and legal costs [#SEC-8K-2026-07-28].

Invalidation

Break below $18 or thesis failure.

What would change my mind?

Higher July guidance floors, stronger projected operating cash flow and lower planned capital spending offer a path to improved free cash flow if new facilities fill and liability costs stabilize [#SEC-8K-2026-07-28].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

$30

p=45%

Bull target

$36

p=30%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

New-bed occupancy versus weak same-facility growth
Higher July guidance floors, stronger projected operating cash flow and lower planned capital spending offer a path to improved free cash flow if new facilities fill and liability costs stabilize [#SEC-8K-2026-07-28].
The packet's $33.79 median target is about 25% above the $26.93 October 1 anchor, but its analyst count and target range are unavailable.

BearKey bullets

Further professional and general liability reserve increases could erode earnings and cash flow; Q2 included a $28.6 million reserve adjustment [#SEC-8K-2026-07-28].
Net leverage was 4.1x adjusted EBITDA at June 30, limiting flexibility if cash-flow guidance slips [#SEC-8K-2026-07-28].
Same-facility patient-day gains may not offset reimbursement timing, pricing pressure or specialty-facility weakness [#SEC-8K-2026-07-28].

WatchKey bullets

Derivative-settlement approval hearing

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $30 (p=45%)

Target spread vs base: +20% / -40%

Scenario probabilities

Bull Target: $36 (p=30%)Base Target: $30 (p=45%)Bear Target: $18 (p=25%)

Commentary

The deterministic prior has turned positive, supported by higher guidance floors and an improved cash-flow outlook, but operating confirmation is incomplete. Packet coverage reports that shares were down 12.8% since Q2 results as of September 24; the October 1 anchor is lower still, without evidence tying that later move to one cause. No reliable post-print analyst-revision series or measured social, options, short-interest or employee sentiment was supplied; zero values above denote unavailable data, not neutral readings.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

New-bed occupancy versus weak same-facility growth

Scenarios

Bull Target (Scenario probability)

$36 / p=30% prob

Base Target (Scenario probability)

$30 / p=45% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-10
Derivative-settlement approval hearing
A court hearing is scheduled for December 10 to consider final approval of a proposed stockholder derivative-action settlement. Preliminary approval is not final resolution, and the filing does not establish that broader litigation or liability risks have ended [#8-K-2026-09-25]. Company notice
Prob 75.00% • Move 3.00% • Priced-in 75.00%
EVENT2026-12-31
2026 guidance and cash-flow delivery
Acadia's July guidance raised the lower bounds for 2026 revenue, adjusted EBITDA and adjusted EPS, increased operating-cash-flow guidance to $350–$400 million, and reduced planned capital spending to $235–$255 million. Delivery against those ranges is the clearest test of the improving cash-flow case [#SEC-8K-2026-07-28]. Company Q2 release
Prob 60.00% • Move 10.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

New-bed occupancy versus weak same-facility growth
2026-12-31
Acadia added 240 licensed beds in Q2 and said it was ramping occupancy at recently opened facilities. Yet same-facility revenue was flat, with patient days up 0.8% and revenue per patient day down 0.8%; sustained utilization and pricing improvement remain unproven [#SEC-8K-2026-07-28].
Prob 55% • Move 12% • Priced-in 40%

Risks

Further professional and general liability reserve increases could erode earnings and cash flow; Q2 included a $28.6 million reserve adjustment [#SEC-8K-2026-07-28].
Net leverage was 4.1x adjusted EBITDA at June 30, limiting flexibility if cash-flow guidance slips [#SEC-8K-2026-07-28].
Same-facility patient-day gains may not offset reimbursement timing, pricing pressure or specialty-facility weakness [#SEC-8K-2026-07-28].
The proposed derivative settlement remains subject to court approval and does not resolve every potential legal exposure [#8-K-2026-09-25].

Peers

Symbol	Summary
BKD	Similar market capitalization but a senior-living operator, not a direct behavioral-health peer; useful only as a loose labor and facility-cost reference.
UHS	More relevant operating comparator than the packet's medtech peers because it operates behavioral-health facilities, though its acute-care business limits direct comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

BKD

Similar market capitalization but a senior-living operator, not a direct behavioral-health peer; useful only as a loose labor and facility-cost reference.

UHS

More relevant operating comparator than the packet's medtech peers because it operates behavioral-health facilities, though its acute-care business limits direct comparability.